Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature

Cancer Treat Rev. 2011 Aug;37(5):366-72. doi: 10.1016/j.ctrv.2010.12.005. Epub 2011 Jan 22.

Abstract

Background: Primary small cell carcinoma of the upper urinary tract (UUT-SCC) is an extremely uncommon disease. The current knowledge of these rare tumors is mainly based on case reports or small series.

Methods: We reported two cases and performed a systematic literature search from 1970 to 2010 for articles on UUT-SCC. Overall, 40 patients with UUT-SCC were reviewed, a database was generated to analyze clinical characteristics, pathological features and therapy outcomes and to attempt in identifying prognostic factors.

Results: For the 39 cases with available data, median age was 66.5 years and male-female ratio was 2:1. An Asian ethnic background was more common (59%). Surgery was the standard treatment given to all patients. In 67% of cases, SCC coexisted with another malignant component, including urothelial carcinoma in 62% of patients. Overall median survival was 15 months and the 1-, 2- and 3-year survival rates were 58.4%, 38.1% and 23.8%, respectively. Of all cases, 53.8% developed detectable metastasis in a median delay of 13 months. Pathological stage was the only significant prognostic factor found (p=0.01). Patients who received adjuvant chemotherapy seem to have a higher median survival comparatively to those who did not receive chemotherapy but this was not statistically significant (24 vs. 12 months, p=0.56).

Conclusions: UUT-SCC is an extremely rare tumor characterized by an aggressive clinical course. Local or distant metastases are frequent and survival is poor. Pathological stage appeared to be a prognostic factor for overall survival.

Publication types

  • Case Reports
  • Review
  • Systematic Review

MeSH terms

  • Aged
  • Biopsy, Needle
  • Carcinoma, Small Cell / mortality*
  • Carcinoma, Small Cell / pathology*
  • Carcinoma, Small Cell / therapy
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Prognosis
  • Rare Diseases
  • Risk Assessment
  • Survival Analysis
  • Ureteral Neoplasms / mortality
  • Ureteral Neoplasms / pathology
  • Ureteral Neoplasms / therapy
  • Urethral Neoplasms / mortality
  • Urethral Neoplasms / pathology
  • Urethral Neoplasms / therapy
  • Urologic Neoplasms / mortality*
  • Urologic Neoplasms / pathology*
  • Urologic Neoplasms / therapy